KR20230145335A - 융합 쿼드라사이클릭 화합물, 조성물 및 그의 용도 - Google Patents

융합 쿼드라사이클릭 화합물, 조성물 및 그의 용도 Download PDF

Info

Publication number
KR20230145335A
KR20230145335A KR1020237026555A KR20237026555A KR20230145335A KR 20230145335 A KR20230145335 A KR 20230145335A KR 1020237026555 A KR1020237026555 A KR 1020237026555A KR 20237026555 A KR20237026555 A KR 20237026555A KR 20230145335 A KR20230145335 A KR 20230145335A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
optionally substituted
mmol
alkylaminoalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237026555A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에이치. 세라노-우
지숑 예
웨이홍 장
Original Assignee
타보메덱스 바이오사이언스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타보메덱스 바이오사이언스 아이엔씨. filed Critical 타보메덱스 바이오사이언스 아이엔씨.
Publication of KR20230145335A publication Critical patent/KR20230145335A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237026555A 2021-01-11 2022-01-10 융합 쿼드라사이클릭 화합물, 조성물 및 그의 용도 Pending KR20230145335A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/071062 2021-01-11
CN2021071062 2021-01-11
PCT/US2022/011824 WO2022150707A1 (en) 2021-01-11 2022-01-10 Fused quadracyclic compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR20230145335A true KR20230145335A (ko) 2023-10-17

Family

ID=82356986

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026555A Pending KR20230145335A (ko) 2021-01-11 2022-01-10 융합 쿼드라사이클릭 화합물, 조성물 및 그의 용도

Country Status (11)

Country Link
US (1) US20240140958A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274833A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504927A (cg-RX-API-DMAC7.html)
KR (1) KR20230145335A (cg-RX-API-DMAC7.html)
CN (1) CN118574834A (cg-RX-API-DMAC7.html)
AU (1) AU2022205678A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023013722A2 (cg-RX-API-DMAC7.html)
CA (1) CA3204167A1 (cg-RX-API-DMAC7.html)
IL (1) IL304142A (cg-RX-API-DMAC7.html)
MX (1) MX2023007992A (cg-RX-API-DMAC7.html)
WO (1) WO2022150707A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
CN118290358A (zh) * 2024-03-06 2024-07-05 江苏医药职业学院 一种制备利奈唑胺关键中间体(s)-5-((苄基氨基)甲基)噁唑烷-2-酮的方法
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) * 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Also Published As

Publication number Publication date
US20240140958A1 (en) 2024-05-02
IL304142A (en) 2023-09-01
WO2022150707A1 (en) 2022-07-14
CN118574834A (zh) 2024-08-30
AU2022205678A1 (en) 2023-08-03
EP4274833A4 (en) 2025-02-19
JP2024504927A (ja) 2024-02-02
EP4274833A1 (en) 2023-11-15
MX2023007992A (es) 2023-09-27
CA3204167A1 (en) 2022-07-14
BR112023013722A2 (pt) 2024-01-30

Similar Documents

Publication Publication Date Title
JP2023144075A (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
KR102821964B1 (ko) 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CN113072542B (zh) RORγt抑制剂及其制备方法和用途
US12565490B2 (en) Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease
JP2018104463A (ja) メタロ−β−ラクタマーゼ阻害剤としての３−テトラゾリル−ベンゼン−１，２−ジスルホンアミド誘導体
CA2856505A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2015008839A1 (ja) Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
AU2014212501A1 (en) Spiro-lactam NMDA receptor modulators and uses thereof
JP6895396B2 (ja) 疾患を処置するためのｇｌｓ１阻害薬
US20250214942A1 (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2022150707A1 (en) Fused quadracyclic compounds, compositions and uses thereof
EP4168114A1 (en) Small molecule modulators of il-17
KR20200128414A (ko) 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체
JP7774579B2 (ja) ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
WO2022150574A1 (en) Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
CN108602822A (zh) 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途
TW201726681A (zh) 稠合四環化合物及其組合物與用途
EA052066B1 (ru) Конденсированные четырехциклические соединения, их композиции и применение
WO2025231457A1 (en) Technologies for modulating citk and cell states
KR20250051678A (ko) 피부과 질환의 국소 치료를 위한 jak1/jak2/tyk2 억제제
CN105801563B (zh) 吡唑类衍生物及其用途
US20230416261A1 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
SG192853A1 (en) Glycine transporter-inhibiting substances
HK40033410B (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902